Loading Page
Dr. Alexander Ja-Ho Chou, MD is a physician provider in New York, NY specializing in physician, pediatric hematology and oncology (cancer care). He graduated from Weill Cornell Medical College in 1998 and has 28 years of experience. Dr. Alexander Ja-Ho Chou, MD is affiliated with NewYork-Presbyterian, Weill Cornell Medicine and Pediatric Hematology/Oncology.
Dr. Alexander Ja-Ho Chou, MD graduated from Weill Cornell Medical College in 1998. He is certified by the American Board of Pediatrics and has a state license in New York.
Medical School: Weill Cornell Medical College (1998)
Board Certification: American Board of Pediatrics
Licensed In: New York
Dr. Alexander Ja-Ho Chou, MD appears to accept the following insurance providers: GHI, Health Insurance Plan of NY (HIP), EmblemHealth, WellCare, Healthspring, AETNA, Quality Health Management (QHM), UnitedHealthcare, United Healthcare, Oxford Health Plans, CIGNA, Local 1199, Fidelis Care, Molina Healthcare, Healthfirst, Anthem Blue Cross Blue Shield, Aetna - NYP, VNSNY CHOICE, Rockefeller University/Luminare, VNS Health, WorldWide Medical, United Healthcare Community Plan (AmeriChoice), United Healthcare Medicare, Medicare Advantage, GHI CBP, United Healthcare Empire Plan, Affinity Health Plan, Medicare, Medicaid, Aetna PPO, Aetna HMO, Aetna-NYP EPO/POS, Aetna Weill Cornell Employee Managed Care Plan, Oxford Health Plans Liberty, Oxford Health Plans Freedom, Aetna Weill Cornell Employee PPO Plan, Rockefeller University - Trustmark, VNSNY CHOICE HMO and Oxford Health Plans Metro/Core/Charter.
According to our sources, Dr. Alexander Ja-Ho Chou, MD accepts the following insurance providers:
Dr. Alexander Ja-Ho Chou, MD does not have any reviews yet, be the first to leave a review of Dr. Alexander Ja-Ho Chou, MD here: Leave a Review
These charts describe general payments received by Dr. Alexander Ja-Ho Chou, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
|
$2,300
DANYELZA $2,300 |
|
|
$100
$100 |
|
|
$25
Blincyto $25 |
|
|
$18
DALVANCE $18 |
| $2,300 | |
| $100 | |
| $43 |
Dr. Alexander Ja-Ho Chou, MD has received 7 research payments totaling $49,500.
Dr. Alexander Chou is a Professor of Pediatrics at Weill Cornell Medicine and an Attending Pediatrician at NewYork-Presbyterian/Weill Cornell Medical Center. He specializes in the care of children with pediatric sarcomas including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, desmoplastic small round cell tumor, alveolar soft part sarcoma, rhabdoid tumors, epithelioid sarcomas, infantile fibrosarcomas, and other rare sarcomas of childhood, and also cares for children with other common solid tumors such as neuroblastoma, Wilm’s tumor, hepatoblastoma, germ cell tumors, and other rarer tumors of childhood.Dr. Chou received his medical degree (M.D.) at Weill Cornell Medical College, Cornell University.  After completing his residency in Pediatrics at NewYork-Presbyterian/Weill Cornell Medical Center, he continued his training and completed a pediatric hematology/oncology fellowship at the joint program at Memorial Sloan Kettering Cancer Center and NewYork-Presbyterian/Weill Cornell Medical Center.  Dr. Chou joined the faculty at Memorial Sloan Kettering Cancer Center (MSKCC) where he served for a decade as a member of the pediatric sarcoma service and in various education leadership roles.  He then  served as clinical director of the pediatric sarcoma service at the Children's Hospital at Montefiore, where he helped establish the Bronx’s first pediatric cancer predisposition clinic. In 2021, he was recruited to rejoin the faculty at Weill Cornell Medicine to provide  direct care for children with solid tumors and serve as the Director for Clinical Operations for Pediatric Oncology.Dr. Chou's research and clinical interests lie in exploring new treatment options for pediatric sarcomas and pediatric solid tumors. In the laboratory, he has sought to characterize the molecular pathways that led to tumor growth and progression. Additionally, he helped develop novel drugs and treatment delivery mechanisms for relapsed pediatric sarcomas.  He is active in regional, national and international collaborative organizations including the Children’s Oncology Group, the American Society of Pediatric Hematology Oncology, and the Connective Tissue Oncology Society.
